26
|
Donagh LM, Gray S, Gallagher M, Ffrench B, Gasch C, Young V, Ryan R, Nicholson S, Leonard N, Finn S, Cuffe S, O’Byrne K, Barr M. P2.02-064 A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Baird A, Keegan N, Barr M, Fishleder S, Idris A, Harrold E, O'Kelly P, Duff E, Lim S, O'Donnell M, Gallagher D, Grant C, Kennedy J, O'Donnell D, Sukor S, O'Brien C, Finn S, Cuffe S. MA 04.10 An Assessment of the Willingness to Provide Serial Bio-Specimens: Experience from an Irish Tertiary Cancer Centre. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Reynolds JV, Preston SR, O’Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O’Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O’Reilly S, O’Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017; 17:401. [PMID: 28578652 PMCID: PMC5457631 DOI: 10.1186/s12885-017-3386-2] [Citation(s) in RCA: 124] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 05/25/2017] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation. The Neo-AEGIS trial, uniquely powered on AEG, and including comprehensive modern staging, compares both these regimens. METHODS This open label, multicentre, phase III RCT randomises patients (cT2-3, N0-3, M0) in a 1:1 fashion to receive CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks). The power calculation is a 10% difference in favour of CROSS, powered at 80%, two-sided alpha level of 0.05, requiring 540 patients to be evaluable, 594 to be recruited if a 10% dropout is included (297 in each group). The primary endpoint is overall survival, with a minimum 3-year follow up. Secondary endpoints include: disease free survival, recurrence rates, clinical and pathological response rates, toxicities of induction regimens, post-operative pathology and tumour regression grade, operative in-hospital complications, and health-related quality of life. The trial also affords opportunities for establishing a bio-resource of pre-treatment and resected tumour, and translational research. DISCUSSION This RCT directly compares two established treatment regimens, and addresses whether radiation therapy positively impacts on overall survival compared with a standard perioperative chemotherapy regimen Sponsor: Irish Clinical Research Group (ICORG). TRIAL REGISTRATION NCT01726452 . Protocol 10-14. Date of registration 06/11/2012.
Collapse
|
29
|
Baird AM, Jarzabek M, Shiels L, Raeppel S, Finn S, Cuffe S, Pass H, Schmitt-Opitz I, Byrne A, Gray S. Targeting the RON/MET/TAM signalling network in mesothelioma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx093.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Lin R, Reid G, Mutti L, Ryan A, Nicholson S, Leonard N, Young V, Ryan R, Finn S, Cuffe S, Gray S. 8: Are circRNAs potentially useful for the early detection of lung cancer? Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30058-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Barr M, Singh S, Foley E, He Y, Young V, Ryan R, Nicholson S, Leonard N, O'Byrne K, Cuffe S, Finn S. 2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30052-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby M, Lubiniecki G, Shentu Y, Rangwala R, Brahmer J. 437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Harrold E, Idris A, Keegan N, Corrigan L, Teo M, Lim S, Duff E, Donnell M, Kennedy J, O'Donnell D, Sukor S, Grant C, Gallagher D, Collier S, Kingston T, O'Dwyer A, Cuffe S. Insomnia prevalence in an oncology patient population: an Irish tertiary referral centre experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csoszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby M, Lubiniecki G, Shentu Y, Rangwala R, Brahmer J. KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.40] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Vlajnic T, Brady L, Casey O, Gately K, Barr M, Cuffe S, Bubendorf L, Finn S. 26P Characteristics of circulating tumor cells (CTCs) in patients with lung cancer. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30140-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Barr M, Foley E, He Y, Young V, Ryan R, Nicholson S, Leonard N, O'Byrne K, Cuffe S, Finn S. 80P XRCC6BP1: A key DNA repair gene in platinum-resistant NSCLC. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30193-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
37
|
Barr M, MacDonagh L, Gray S, Reidy M, Sui JSY, Nicholson S, Leonard N, O'Byrne K, Cuffe S, Finn S. 70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response? J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30183-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
MacDonagh L, Gray S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, O'Byrne K, Barr M. 6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30023-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Barr M, Foley E, He Y, Young V, Ryan R, Nicholson S, Leonard N, O'Byrne K, Finn S, Cuffe S. 4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30021-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Lyons J, O'Brien C, Krussel S, Finn S, Cuffe S, O'Connell F, Gately K. 10 Multiplex genotyping of matched EBUS TBNA and cfDNA samples in advanced NSCLC patients. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30027-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
41
|
Ged Y, Crowley B, Cuffe S, Harrold E, Keegan N, Kennedy M, Mustafa M, Norris S, O'Donnell D. 1233 Hepatitis screening in solid tumours: Results in an Irish cancer centre. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30537-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Stahel R, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix S, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina M, Rosell R. 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30068-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Martin P, Brown MC, Espin-Garcia O, Cuffe S, Pringle D, Mahler M, Villeneuve J, Niu C, Charow R, Lam C, Shani RM, Hon H, Otsuka M, Xu W, Alibhai S, Jenkinson J, Liu G. Patient preference: a comparison of electronic patient-completed questionnaires with paper among cancer patients. Eur J Cancer Care (Engl) 2015; 25:334-41. [PMID: 25899560 DOI: 10.1111/ecc.12318] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/09/2015] [Indexed: 12/15/2022]
Abstract
In this study, we compared cancer patients preference for computerised (tablet/web-based) surveys versus paper. We also assessed whether the understanding of a cancer-related topic, pharmacogenomics is affected by the survey format, and examined differences in demographic and medical characteristics which may affect patient preference and understanding. Three hundred and four cancer patients completed a tablet-administered survey and another 153 patients completed a paper-based survey. Patients who participated in the tablet survey were questioned regarding their preference for survey format administration (paper, tablet and web-based). Understanding was assessed with a 'direct' method, by asking patients to assess their understanding of genetic testing, and with a 'composite' score. Patients preferred administration with tablet (71%) compared with web-based (12%) and paper (17%). Patients <65 years old, non-Caucasians and white-collar professionals significantly preferred the computerised format following multivariate analysis. There was no significant difference in understanding between the paper and tablet survey with direct questioning or composite score. Age (<65 years) and white-collar professionals were associated with increased understanding (both P = 0.03). There was no significant difference in understanding between the tablet and print survey in a multivariate analysis. Patients overwhelmingly preferred computerised surveys and understanding of pharmacogenomics was not affected by survey format.
Collapse
|
44
|
Baird AM, Godwin P, Heavey S, Barr M, Umezawa K, Cuffe S, Finn S, O'Byrne K, Gately K. 4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer. Lung Cancer 2015. [DOI: 10.1016/s0169-5002(15)50004-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
He Y, O'Byrne K, Cuffe S, Finn S, Barr M. 2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer. Lung Cancer 2015. [DOI: 10.1016/s0169-5002(15)50002-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Heavey S, Dowling P, Barr M, Cuffe S, Finn S, O'Byrne K, Gately K. 5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines. Lung Cancer 2015. [DOI: 10.1016/s0169-5002(15)50005-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Baird AM, Godwin P, Heavey S, Umezawa K, Barr M, Richard D, Cuffe S, Finn S, O'Byrne K, Gately K. 1 Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)00036-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Heavey S, Barr M, Finn S, Cuffe S, O'Byrne K, Gately K. 10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70011-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
49
|
MacDonagh L, Gray S, Cuffe S, Finn S, O'Byrne K, Barr M. 5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70006-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Barr M, Batina M, Cuffe S, Finn S, O'Byrne K. 2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells. Lung Cancer 2014. [DOI: 10.1016/s0169-5002(14)70003-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|